- Bacillus Calmette-Guérin (BCG)
- Cystoscopy
- Radical Cystectomy
- Transurethral Resection of Bladder Tumor (TURBT)
- Urologic Oncology
- Non-Muscle Invasive Bladder Cancer (NMIBC)
- Intravesical Therapy
- Bladder Cancer
Dr. Ashish Kamat discusses contemporary management of high-risk, non-muscle-invasive bladder cancer (NMIBC) and his thoughts into the future of this arena.
This podcast is supported by
Timestamps
Resources
More about this episode
Dr. Kamat explores the evolving role of BCG and potential alternative therapies such as gemcitabine and docetaxel. He also covers effective clinical management, emerging clinical trials, and nuanced decision-making principles for radical cystectomy. Finally, the conversation touches on Dr. Kamat’s expert insights regarding the future of NMIBC management, including predictive biomarkers and personalized medicine.


